Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months
about
Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trialsThe Obesity Epidemic and Consequences for Rheumatoid Arthritis CareResponse to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'.The challenging interplay between rheumatoid arthritis, ageing and comorbidities.Weight Gain and Hair Loss during Anti-TNF Therapy.Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biologicalsEffect of inhibition of interleukin-12/23 by ustekinumab on the expression of leptin and leptin receptor in human THP-1 macrophagesGreater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.Insulin-like Growth Factor 1 and Adiponectin and Associations with Muscle Deficits, Disease Characteristics, and Treatments in Rheumatoid Arthritis.Rheumatoid arthritis impacts on the independent relationships between circulating adiponectin concentrations and cardiovascular metabolic riskLong-term treatment of rheumatoid arthritis with adalimumab.Psoriasis comorbidities: complications and benefits of immunobiological treatmentAdipokines as potential biomarkers in rheumatoid arthritisWhat's new in our understanding of the role of adipokines in rheumatic diseases?Emerging role of leptin in rheumatoid arthritis.Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis.Fenofibrate administration to arthritic rats increases adiponectin and leptin and prevents oxidative muscle wasting.Are the benefits of a high-intensity progressive resistance training program sustained in rheumatoid arthritis patients? A 3-year followup study.TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.Association between leptin and IL-6 concentrations with cardiovascular risk in patients with rheumatoid arthritis.Body composition of rheumatoid arthritis patients in the City of Cape Town, South Africa.The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis
P2860
Q27025358-C1AC2DA8-7994-47EF-9225-BA033A5F0D4DQ28074864-BD5B813F-DF3A-4C5C-B13F-46E97BD963C0Q35092979-508D7CCA-E43C-4307-9EC1-1A9F80452379Q36000249-5932B672-2178-4B5F-ACFB-1F1E127FD9C9Q36167360-C4224BAF-13BC-4E1C-8D6D-2B1779A0A1FFQ36238859-D7B0E7E6-AA72-4C58-8F3E-3420C4FF4382Q36387222-5F509064-64F9-4B5D-80D0-1A5609C640BEQ36732733-0D89105A-D91D-449D-BF4D-606F82FBF1CDQ36732747-B13D776C-F25F-45F1-879B-11D658591166Q36830486-D434668B-E2C0-43DF-A881-2918F63E3641Q37358278-B9372B13-3488-4E78-9122-E23AE535870EQ37540440-5B675D2D-E63A-4F2B-B3C7-860989408E6DQ37700750-46780DD1-9E33-4547-B8D9-8322DD9964B0Q37909903-3B826E17-CAF5-49F1-B1CA-B2EA6006D0E4Q38209820-C9B66310-ADA8-4424-AD5A-D1CF69138EE4Q38323310-F5F22077-714B-4F9A-AD0D-8FE63B73F4AAQ40079134-58F83229-0453-4B9B-A808-2DB7BAAC30B2Q41485464-E3DB98F0-CD58-470C-BA4F-5BE669F8F62BQ42153233-2F5D6E01-799B-4B00-9DED-5BBBFC9655E9Q43907775-4E5CB23D-1D71-4244-B516-AADCE5006C39Q43951812-E94501EA-D227-4AC4-B959-8BFCA0E20F32Q47203093-20BAE444-9F11-4FB2-93EC-546815E0B2CCQ47349081-6EC695AF-9AF4-4914-8109-DA0A60CFF709Q47628090-04B10EB9-AF10-4D98-A320-FF91664A8B67Q50756971-24027376-4682-4795-AD44-CCFCFF14532EQ58727105-076902A8-C0C2-4252-B027-565FFF7EC434
P2860
Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Infliximab therapy increases b ...... andomised study over 21 months
@ast
Infliximab therapy increases b ...... andomised study over 21 months
@en
Infliximab therapy increases b ...... andomised study over 21 months
@nl
type
label
Infliximab therapy increases b ...... andomised study over 21 months
@ast
Infliximab therapy increases b ...... andomised study over 21 months
@en
Infliximab therapy increases b ...... andomised study over 21 months
@nl
prefLabel
Infliximab therapy increases b ...... andomised study over 21 months
@ast
Infliximab therapy increases b ...... andomised study over 21 months
@en
Infliximab therapy increases b ...... andomised study over 21 months
@nl
P2093
P2860
P356
P1476
Infliximab therapy increases b ...... andomised study over 21 months
@en
P2093
Birgitta Tengstrand
Inga-Lill Engvall
Ingiäld Hafström
P2860
P2888
P356
10.1186/AR3169
P577
2010-10-21T00:00:00Z
P5875
P6179
1046376225